To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: AAD: Tazarotene Gel As Effective As Tretinoin Gel For Facial Acne URL: http://www.pslgroup.com/dg/20258E.htm Doctor's Guide July 31, 2001
By Ed Susman Special to DG News
ANAHEIM, CA -- July 31, 2001 -- In a head-to-head comparison study, tazarotene 0.1% gel was at least as effective as tretinoin 0.025% gel in treating patients with facial acne vulgaris.
"The results from this study confirm those from an identical study performed previously," said Dr. Nicholas Lowe, clinical professor of medicine at the UCLA School of Medicine, Los Angeles.
"Both studies demonstrate that once-daily tazarotene 0.1% gel can achieve a significantly greater reduction in non-inflammatory lesion count than once-daily tretinoin 0.025% gel. Tazarotene 0.1% get is also at least as effective as tretinoin 0.025% gel in reducing the total inflammatory lesion count."
Dr. Lowe presented his findings today (July 31) during a poster session at the summer scientific meeting of the American Academy of Dermatology, in Anaheim, California.
In the multicenter, double-blind, randomized, parallel-group trial, patients 12 years or older who had mild to moderate facial acne were recruited. To be eligible for the trial, patients were required to show 10 to 60 facial inflammatory lesions; 10 to 200 non-inflammatory lesions (open and closed comedones); and no more than two facial nodular cystic lesions.
In addition, patients discontinued other topical anti-acne medications for two weeks, were off systemic antibiotics for 30 days, and were off oral retinoids for two years.
The subjects applied the gels once daily during the evening for up to 12 weeks.
Through the course of the treatment, patients using tazarotene showed a statistically significant reduction in non-inflammatory lesions after four weeks when compared with tretinoin, and that reduction continued at week eight and at week 12. At week 12, Dr. Lowe said the patients using tazarotene had a 54 percent reduction in the lesions compared with a 27 percent reduction with tretinoin.
In patients with inflammatory lesions, there was a greater reduction with tazarotene than with tretinoin (38 percent versus 14 percent, respectively) but Dr. Lowe said the differences in this category did not reach statistical significance.
"Both treatments were well-tolerated," he said, "with mean scores for peeling, erythema, dryness and burning never exceeding mild levels." He said those results confirmed previous "split-face" studies.
The research was funded by an unrestricted educational grant from Allegan Skin Care, of Irvine, California, the manufacturer of tazarotene. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.